Multiple myeloma – DREAMM-7 update
Prof Claudio Cerchione, haematologist at the Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy, one of the authors of the DREAMM7 study, gave a summary
From 31 May till 4 June 2024: HIGHLIGHTS FROM ASCO
Your direct line with Chicago
The American Society of Clinical Oncology (ASCO) 2024 brings together leading experts in the different fields of cancer from around the world. And, as usual, they gather together in Chicago, USA. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
With the support of:
In-depth stories
Prof Claudio Cerchione, haematologist at the Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy, one of the authors of the DREAMM7 study, gave a summary
Prof Claudio Cerchione, a haematologist at the Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori in Meldola, Italy, presented pioneering research at the ASCO24 rapid oral abstract
Project in the spotlight
Dr Lucia Perez-Lamas, a haematologist at the Puerta de Hierro University Hospital in Madrid, Spain, presented real-world evidence on the use of momelotinib in myelofibrosis (MF) patients with anaemia.
Dr Adriano Salaroli, a haematologist at the Institut Jules Bordet in Brussels, provides an update on cytopenic myelofibrosis, emphasising the need for increased awareness regarding this specific subtype of myelofibrosis.
Dr Marie Vercruyssen, a haematologist at the Institut Jules Bordet in Brussels, summarised the outcomes of the IMROZ trial, which evaluated the addition of the anti-CD38 monoclonal antibody isatuximab to
Dr Sigrún Thorsteinsdóttir, a haematologist at Rigshospitalet in Copenhagen, Denmark, also holds a position as a postdoctoral researcher in the iStopMM study at the University of Iceland. The iSTOPMM study
Dr Hanne Norseth, a haematologist at the Oslo Myeloma Center in Norway, presented the results of the phase I/II TG01 study. This study evaluates the safety and efficacy of the
At the EHA 2024 conference, Prof Dr Xavier Leleu, Head of the Myeloma Clinic and Department of Haematology at the University Hospital of Poitiers (France), presented the results of the
Prof Dr Claudio Cerchione, a haematologist at the Istituto Romagnolo per lo Studio dei Tumori in Meldola, Italy, highlights the necessity for novel treatment combinations in lenalidomide-refractory MM patients. Belantamab
During EHA 2024, an entire session was dedicated to the management of difficult to treat multiple myeloma (MM) populations. In this session, Dr Claudia Stege, haematologist at the Erasmus Medical
In-depth stories
Dr Lucia Perez-Lamas, a haematologist at the Puerta de Hierro University Hospital in Madrid, Spain, presented real-world evidence on the use of momelotinib in myelofibrosis (MF) patients with anaemia.
Dr Adriano Salaroli, a haematologist at the Institut Jules Bordet in Brussels, provides an update on cytopenic myelofibrosis, emphasising the need for increased awareness regarding this specific subtype of myelofibrosis.
Dr Marie Vercruyssen, a haematologist at the Institut Jules Bordet in Brussels, summarised the outcomes of the IMROZ trial, which evaluated the addition of the anti-CD38 monoclonal antibody isatuximab to
Dr Sigrún Thorsteinsdóttir, a haematologist at Rigshospitalet in Copenhagen, Denmark, also holds a position as a postdoctoral researcher in the iStopMM study at the University of Iceland. The iSTOPMM study
Dr Hanne Norseth, a haematologist at the Oslo Myeloma Center in Norway, presented the results of the phase I/II TG01 study. This study evaluates the safety and efficacy of the
At the EHA 2024 conference, Prof Dr Xavier Leleu, Head of the Myeloma Clinic and Department of Haematology at the University Hospital of Poitiers (France), presented the results of the
Prof Dr Claudio Cerchione, a haematologist at the Istituto Romagnolo per lo Studio dei Tumori in Meldola, Italy, highlights the necessity for novel treatment combinations in lenalidomide-refractory MM patients. Belantamab
During EHA 2024, an entire session was dedicated to the management of difficult to treat multiple myeloma (MM) populations. In this session, Dr Claudia Stege, haematologist at the Erasmus Medical
Poster selection
Dr Gabriel Brisou presents preliminary findings on the utilization of axi-cel in the second-line treatment of patients with early R/R LBCL. In France, real-world data encompassing all patients subjected to
Dr Cecilie Blimark, haematologist at the Sahlgrenska University Hospital in Sweden summarized her extensive population-based investigation encompassing symptomatic MM patients from the Swedish Myeloma Registry, ensuring a robust 98% coverage
Dr Margo Aertgeerts from UZ Leuven presented her PhD research in ALL, the most prevalent cancer in the pediatric population. The aetiology of ALL involves the incremental acquisition of mutations
T-ALL represents a highly aggressive haematological malignancy, characterized by an unmet clinical need, particularly in refractory patients or those resistant to standard treatments. Dr Tim Pieters, PhD at Ghent University
André De Almeida, PhD student at the University Hospital Ghent presented his research on investigating the role of SOX11 in T-ALL, which is motivated by its expression within a distinct
Approximately 30% of pediatric AML patients encounter relapse, emphasizing the imperative need for refining risk stratification in this cohort. Consequently, Zhiyao Ren, PhD student at University Hospital Ghent, constructed a
An innovative decentralized and automated PoC manufacturing paradigm was devised to facilitate the expeditious administration of freshly prepared autologous CAR-T therapies within a 7-day timeframe following apheresis in patients diagnosed
Dr Frida Bugge Askeland, associated research doctor and PhD student at the Oslo Myeloma Center in Norway summarised the REST study.
In Norway, the use of VRd (bortezomib, lenalidomide and